Age-related macular degeneration: a target for nanotechnology derived medicines

David G Birch¹, Fong Qi Liang²

¹Retina Foundation of the Southwest, Dallas, TX and Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX, USA; ²Advanced Vision Therapies, Inc Gaithersburg, MD, USA

Abstract: Despite the fact that the retina is a fairly accessible portion of the central nervous system, there are virtually no treatments for early age-related macular degeneration (AMD). AMD is a degenerative retinal disease that causes progressive loss of central vision and is the leading cause of irreversible vision loss and legal blindness in individuals over the age of 50. Both environmental and genetic components play a role in its development. AMD is a multifactorial disease with characteristics that include drusen, hyperpigmentation and/or hypopigmentation of the retinal pigment epithelium (RPE), geographic atrophy and, in a subset of patients, latestage choroidal neovascularization (CNV). Drugs that inhibit vascular endothelial growth factor (VEGF) have proven effective in treating late-stage CNV, but optimal means of drug delivery remains to be determined. Microscopic particles, whose size is on the nanometer scale, show considerable promise for drug delivery to the retina, for gene therapy, and for powering prosthetic “artificial retinas.” This article summarizes the pathophysiology of AMD stressing potential applications from nanotechnology.

Keywords: macular, nanotechnology, AMD, retinal degeneration, gene therapy